Valuation ratios measure the quantity of an asset or flaw (e.g., earnings) associated with ownership of a specified claim (e.g., a share of ownership of the enterprise).
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Historical Valuation Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The valuation ratios exhibit varied trends over the observed period, spanning from March 31, 2022, to December 31, 2025. Generally, the initial period through December 2022 demonstrates relative stability, followed by increases in most ratios through June 2023. A subsequent period of decline is then observed, culminating in a rebound by the end of 2025.
- Price to Earnings (P/E) Ratio
- The P/E ratio increased from 25.48 in March 2022 to a peak of 36.16 in June 2023. This was followed by a substantial decrease, reaching a low of 16.01 in June 2025, before recovering to 29.89 by December 2025. This suggests fluctuating investor confidence in earnings or changes in earnings expectations over the period.
- Price to Operating Profit (P/OP) Ratio
- Similar to the P/E ratio, the P/OP ratio shows an upward trend through June 2023, rising from 21.33 to 30.47. A subsequent decline is evident, reaching 28.05 in September 2025, and then a further decrease to 24.21 in December 2025. The pattern mirrors the P/E ratio, indicating a connection between market valuation and operating profitability.
- Price to Sales (P/S) Ratio
- The P/S ratio experienced a moderate increase from 4.42 in March 2022 to 4.93 in December 2022, followed by a slight dip and then a rise to 5.58 in March 2025. It then decreased to 4.40 by December 2025. This suggests a changing valuation relative to revenue, potentially influenced by growth expectations or competitive pressures.
- Price to Book Value (P/BV) Ratio
- The P/BV ratio generally decreased over the observed period. Starting at 5.56 in March 2022, it declined to 4.25 in September 2025, and then further to 3.74 in December 2025. This indicates a diminishing premium investors are willing to pay for the net asset value of the company, potentially reflecting concerns about asset utilization or future returns on equity.
Overall, the period between March 2022 and June 2023 appears to be characterized by increasing valuation multiples, while the subsequent period through June 2025 shows a general contraction. The final quarter of 2025 indicates a potential stabilization or modest recovery in valuation metrics.
Price to Earnings (P/E)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Net earnings (in millions) | |||||||||||||||||||||
| Earnings per share (EPS)2 | |||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||
| P/E ratio4 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| P/E Ratio, Competitors5 | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
EPS
= (Net earningsQ4 2025
+ Net earningsQ3 2025
+ Net earningsQ2 2025
+ Net earningsQ1 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Abbott Laboratories Quarterly or Annual Report.
4 Q4 2025 Calculation
P/E ratio = Share price ÷ EPS
= ÷ =
5 Click competitor name to see calculations.
The price-to-earnings (P/E) ratio exhibited considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicated a decreasing trend through the first half of 2022, followed by a period of relative stability before increasing again towards the end of 2022. A significant shift occurred in early 2023, with the P/E ratio reaching its highest points during the first two quarters, before declining and stabilizing in the latter half of the year. The final period, from early 2024 through the end of 2025, demonstrates a notable decrease followed by a substantial increase in the final quarter.
- Overall Trend
- The P/E ratio generally decreased from the beginning of the period to the end of 2023, then increased significantly in the final quarter of 2025. The ratio experienced substantial volatility, lacking a consistently upward or downward trajectory.
- 2022 Performance
- The P/E ratio began at 25.48 in March 2022 and decreased to 22.24 by June 2022, continuing to 21.95 by September 2022. A slight increase was observed in December 2022, reaching 26.76. This suggests a period of decreasing investor valuation relative to earnings, followed by a modest recovery.
- 2023 Fluctuations
- The P/E ratio peaked in the first half of 2023, reaching 33.21 and 36.16 in March and June, respectively. This was followed by a decline to 31.95 and 34.57 in the subsequent quarters. The elevated values in the first half of 2023 may indicate increased investor optimism or a temporary surge in share price relative to earnings.
- Recent Performance (2024-2025)
- The P/E ratio decreased substantially throughout most of 2024, reaching a low of 15.48 in September 2025. However, a significant increase was observed in December 2025, with the ratio climbing to 29.89. This late-year surge could be attributed to various factors, including positive earnings surprises, market sentiment shifts, or anticipation of future growth.
- Relationship to Earnings
- The fluctuations in the P/E ratio are influenced by both changes in share price and earnings per share. While the share price generally increased over the period, the earnings per share experienced more pronounced variations, particularly the substantial increase in 2024, which contributed to the lower P/E ratios observed during that year. The final quarter of 2025 saw a decrease in EPS alongside an increase in share price, resulting in a higher P/E ratio.
In conclusion, the P/E ratio demonstrates a complex pattern of changes, influenced by both share price and earnings. The observed volatility suggests that investor sentiment and expectations regarding future earnings growth have been dynamic throughout the analyzed period.
Price to Operating Profit (P/OP)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Operating earnings (in millions) | |||||||||||||||||||||
| Operating profit per share2 | |||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||
| P/OP ratio4 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| P/OP Ratio, Competitors5 | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
Operating profit per share
= (Operating earningsQ4 2025
+ Operating earningsQ3 2025
+ Operating earningsQ2 2025
+ Operating earningsQ1 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Abbott Laboratories Quarterly or Annual Report.
4 Q4 2025 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= ÷ =
5 Click competitor name to see calculations.
The Price to Operating Profit (P/OP) ratio exhibited considerable fluctuation throughout the observed period, spanning from March 31, 2022, to December 31, 2025. Initially, the ratio demonstrated a decreasing trend, followed by periods of increase and relative stabilization, ultimately concluding with a decline.
- Initial Decline (Mar 31, 2022 – Jun 30, 2022)
- The P/OP ratio began at 21.33 and decreased to 18.63 over the first two quarters. This suggests a relative decrease in the price investors were willing to pay for each dollar of operating profit during this period, potentially reflecting evolving market expectations or initial concerns regarding future profitability.
- Fluctuation and Increase (Sep 30, 2022 – Jun 30, 2023)
- From September 30, 2022, through June 30, 2023, the ratio experienced volatility, moving from 18.35 to a peak of 30.47. This increase indicates growing investor confidence, potentially driven by positive company performance or broader market sentiment. The period also included a notable increase from 27.48 to 30.47 between September 30, 2022, and June 30, 2023.
- Stabilization and Subsequent Decline (Sep 30, 2023 – Dec 31, 2025)
- Following the peak, the P/OP ratio stabilized somewhat, fluctuating between 28.05 and 34.28 through December 31, 2024. However, a clear downward trend emerged in the final quarters, with the ratio decreasing from 34.28 to 24.21 by December 31, 2025. This final decline could indicate renewed investor caution, potentially linked to concerns about future operating profit growth or increased risk perception.
- Relationship to Operating Profit per Share
- The fluctuations in the P/OP ratio generally mirrored the changes in the share price, while the operating profit per share exhibited a more consistent, albeit modest, upward trend. The larger swings in the P/OP ratio suggest that investor sentiment and external factors played a significant role in valuation, rather than solely relying on the underlying operating profitability.
In summary, the P/OP ratio demonstrated a dynamic pattern over the analyzed timeframe. While periods of increased valuation were observed, the concluding trend indicates a potential shift in investor perception, resulting in a lower premium placed on each dollar of operating profit.
Price to Sales (P/S)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Net sales (in millions) | |||||||||||||||||||||
| Sales per share2 | |||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||
| P/S ratio4 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| P/S Ratio, Competitors5 | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
Sales per share
= (Net salesQ4 2025
+ Net salesQ3 2025
+ Net salesQ2 2025
+ Net salesQ1 2025)
÷ No. shares of common stock outstanding
= ( + + + )
÷ =
3 Closing price as at the filing date of Abbott Laboratories Quarterly or Annual Report.
4 Q4 2025 Calculation
P/S ratio = Share price ÷ Sales per share
= ÷ =
5 Click competitor name to see calculations.
The price-to-sales (P/S) ratio exhibited fluctuations over the observed period, spanning from March 31, 2022, to December 31, 2025. Initial values indicated a gradual decline followed by periods of increase and subsequent stabilization, ultimately concluding with a decrease in the final reported quarter.
- Initial Decline (Q1 2022 - Q3 2022)
- The P/S ratio began at 4.42 in March 2022 and decreased to 3.85 by September 2022. This suggests a relative decrease in the valuation assigned to each dollar of sales during this period. This decline occurred alongside a slight fluctuation in sales per share.
- Recovery and Peak (Q4 2022 - Q4 2023)
- From December 2022 to December 2023, the P/S ratio experienced a recovery, peaking at 5.58 in December 2023. This increase indicates growing investor confidence or expectations regarding future sales growth relative to the share price. The share price also demonstrated a significant increase during this timeframe.
- Stabilization and Subsequent Decline (Q1 2024 - Q4 2025)
- Following the peak, the P/S ratio stabilized in the first half of 2024, hovering around 4.5. However, a downward trend emerged in the latter half of 2024 and continued into 2025, concluding at 4.40 in December 2025. This suggests a potential shift in investor sentiment or a reassessment of the company’s growth prospects. Sales per share continued to increase throughout this period, but the share price experienced a more pronounced decline.
Overall, the P/S ratio demonstrated a cyclical pattern. The initial decline was followed by a period of growth, culminating in a peak, and then a subsequent period of stabilization and decline. The ratio’s movement does not appear to be directly correlated with changes in sales per share, suggesting other factors, such as broader market conditions or investor expectations, may have played a significant role in valuation.
- Sales per Share Trend
- Sales per share generally increased throughout the observed period, moving from 25.42 in March 2022 to 25.51 in December 2025. This indicates consistent revenue generation relative to the number of outstanding shares. However, this increase did not consistently translate into a higher P/S ratio, particularly in the later quarters.
The fluctuations in the P/S ratio warrant further investigation to determine the underlying drivers. A comprehensive analysis should consider macroeconomic factors, industry trends, and company-specific developments to provide a more nuanced understanding of the observed patterns.
Price to Book Value (P/BV)
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. shares of common stock outstanding1 | |||||||||||||||||||||
| Selected Financial Data (US$) | |||||||||||||||||||||
| Total Abbott shareholders’ investment (in millions) | |||||||||||||||||||||
| Book value per share (BVPS)2 | |||||||||||||||||||||
| Share price1, 3 | |||||||||||||||||||||
| Valuation Ratio | |||||||||||||||||||||
| P/BV ratio4 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| P/BV Ratio, Competitors5 | |||||||||||||||||||||
| Elevance Health Inc. | |||||||||||||||||||||
| Intuitive Surgical Inc. | |||||||||||||||||||||
| Medtronic PLC | |||||||||||||||||||||
| UnitedHealth Group Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Data adjusted for splits and stock dividends.
2 Q4 2025 Calculation
BVPS = Total Abbott shareholders’ investment ÷ No. shares of common stock outstanding
= ÷ =
3 Closing price as at the filing date of Abbott Laboratories Quarterly or Annual Report.
4 Q4 2025 Calculation
P/BV ratio = Share price ÷ BVPS
= ÷ =
5 Click competitor name to see calculations.
The price-to-book value (P/BV) ratio for the analyzed period demonstrates fluctuations, generally trending downwards over the observed timeframe. Initial values indicate a P/BV around 5.5 in the first quarter of 2022, followed by a period of relative stability before a noticeable decline towards the end of 2023. The latter part of the period shows continued decrease, culminating in a P/BV of 3.74 in the final quarter of 2025.
- Initial Period (Mar 31, 2022 – Dec 31, 2022)
- The P/BV ratio began at 5.56 and experienced moderate volatility, ranging from a low of 4.85 to a high of 5.56. This suggests a relatively consistent market valuation of the company’s net asset value during this period. The fluctuations, while present, remained within a limited range.
- Transitional Phase (Mar 31, 2023 – Dec 31, 2023)
- A downward trend became more apparent starting in the first quarter of 2023. The P/BV ratio decreased from 5.21 to 5.12, then experienced a more significant drop to 4.40 by the third quarter of 2023, before a partial recovery to 5.12 in the fourth quarter. This period indicates increasing investor skepticism or a shift in market perception regarding the company’s asset valuation.
- Declining Trend (Mar 31, 2024 – Dec 31, 2025)
- The P/BV ratio continued its decline throughout 2024 and 2025. From a value of 4.75 in the first quarter of 2024, it steadily decreased to 3.74 in the final quarter of 2025. This consistent downward movement suggests a growing disconnect between the market price of the shares and the company’s book value, potentially reflecting concerns about future earnings potential or overall market conditions. The rate of decline appears to accelerate in the latter half of the period.
- Book Value per Share (BVPS) Trend
- Concurrently, the book value per share exhibited a consistent upward trend throughout the analyzed period, increasing from 20.22 to 30.00. This increase in BVPS contrasts with the declining P/BV ratio, further emphasizing the widening gap between market valuation and net asset value. The increasing BVPS suggests the company is effectively building equity, but this is not being reflected in the share price relative to that equity.
In summary, the P/BV ratio demonstrates a clear downward trajectory over the analyzed period, despite a concurrent increase in book value per share. This divergence warrants further investigation to understand the underlying factors driving the market’s changing perception of the company’s value.